Study study type
PathologyT1T0Patientssample sizesROB Results

mBC - Triple negative (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - (neo)adjuvant (NA)

versus carboplatin, pegylated liposomal doxorubicin and cyclophosphamide
carboplatin
NSABP B-59/GBG 96-GeparDouze, 2018
  NCT03281954		RCTmBC - Triple negative (TNBC) - (neo)adjuvant (NA)atezolizumab plus NAC (neoadjuvant chemotherapy)placebo plus NACPatients with centrally-confirmed ER-neg, PR-neg, HER2-neg invasive breast cancer by ASCO/CAP guidelines, stage T2 or T3 if cN0 or cN1 with negative biopsy or T1c, T2, or T3 if cN1 with positive biopsy or cN2 or cN3. LVEF > 55% and no significant cardiac history773 / 777NA
 inconclusive
  • inconclusive 20 % decrease in events or deaths (EFS) (PE)

la/mBC - TNBC - L2 - all population breast cancer - triple negative breast cancer - triple negative metastatic mBC-Triple negative (TNBC) - 2nd Line (L2) la/mBC - TNBC - L2 - all population

versus carboplatin, gemcitabine
carboplatin
IMpassion-132 (ITT population), 2024
  NCT03371017		RCTla/mBC - TNBC - L2 - all populationatezolizumab plus SOCplacebo plus SOCPatients with locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy or surgery in early stage297 / 298low
 inconclusive
    no statistically significant result
OS was not improved by adding atezolizumab to chemotherapy for rapidly relapsing PD-L1-positive TNBC
versus carboplatin
carboplatin
TBCRC, 2024

  NCT03206203		RCTla/mBC - TNBC - L2 - all populationcarboplatin atezolizumab, 1200 mgcarboplatinclinical stage IV or metastatic invasive TN breast cancer. 0 to 1 prior treatments for metastatic disease, and no prior carboplatin in the metastatic setting or prior immune-oncology treatment were eligible. Patients were not stratified by PD-L1 status.56 / 50high
 inconclusive
  • suggested 54 % decrease in deaths (OS)
  • inconclusive 34 % decrease in progression or deaths (PFS) (PE)

la/mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative breast cancer - triple negative metastatic mBC-Triple negative (TNBC) - 2nd Line (L2) la/mBC - TNBC - L2 - PDL1 positive

versus carboplatin, gemcitabine
carboplatin
IMpassion-132 (PD-L1 positive population), 2024
  NCT03371017		RCTla/mBC - TNBC - L2 - PDL1 positiveatezolizumab plus SOCplacebo plus SOCPatients with locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy or surgery in early stage177 / 177low
 inconclusive
  • inconclusive 7 % decrease in deaths (OS) (PE)

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)

versus Standard of Care (SoC)
gemcitabine plus platin
BCTOP-T-A01 arm A/B, 2024
  NCT02641847		RCTes-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatinepiribucine and cyclophosphamide followed by docetaxelFemale patients aged 18-70 years with early triple negative breast cancer after definitive surgery.166 / 170NA
 trade-off
  • demonstrated 49 % decrease in RFS/DFS (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons